The primary objective of the BEST trial is to determine prospectively whether the addition of beta-blockers to standard therapy reduces the total mortality of patients with moderate to severe chronic congestive heart failure. Patients are randomized to either bucindolol, a beta blocker, or placebo in a double blind design and stratified by etiology of heart failure, gender, ejection fraction, race, and the treating hospital.
Showing the most recent 10 out of 600 publications